CytomX Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- As of September 30th, 2026, CytomX had $348 million in cash, cash equivalents, and investments, versus $330 million in cash as of June 30th, 2026; the September 30th balance included $37 million received from Regeneron following its selection of 2 additional targets under the recently expanded collaboration.
- 3rd quarter 2026 revenue was $1.7 million, compared with $6 million in the 3rd quarter of 2025, primarily reflecting the conclusion of the Astellas collaboration in the 2nd quarter of 2026.
- 3rd quarter operating expenses were $25.2 million, compared with $21.7 million in the 3rd quarter of 2025; research and development expenses were $16.5 million, and general and administrative expenses were $8.7 million.
- Barsetta M monotherapy Phase 1 has enrolled more than 100 patients across dose escalation, expansion, and optimization cohorts; most patients had received 3 or more prior treatments in the metastatic setting.
- CytomX is evaluating Barsetta M at 8.6 and 10 milligrams per kilogram every 3 weeks, using adjusted ideal body weight dosing and upfront prophylaxis to manage gastrointestinal adverse events.
- CytomX initiated Phase 1 cohorts for Barsetta M in unselected gastric and gastroesophageal junction cancer and EpCAM-selected pancreatic ductal adenocarcinoma and biliary tract cancer, with an initial plan to enroll approximately 20 patients per tumor type.
- The CX801 Phase 1 study continues to enroll patients in monotherapy and Keytruda combination cohorts in checkpoint refractory melanoma.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics Third Quarter 2026 Financial Results Call. Please be advised that today's call is being recorded. I would now like to hand the call over to your host for today, Chris Ogden, CytomX's Chief Financial Officer. Please go ahead. Thank you.
Good afternoon, and thank you for joining us. Before we begin, I would like to remind everyone that during this call, we will be making forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict, and many of which are outside of our control. Important risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise. Earlier this afternoon, we filed our quarterly report on Form 10-Q for Q3 2026 and issued a press release with a summary of our third quarter 2026 financial results and business highlights. We encourage everyone to read today's filing and press release.
Additionally, the press release, recording of this call, and our SEC filings can be found under the Investors and News section of our website. With me on the call today is Dr. Sean McCarthy, CytomX's Chief Executive Officer and Chairman. Sean will provide an update on our pipeline and company progress before I cover the financials for the quarter. We will then conclude with a Q&A session. With that, I'll turn the call over to Sean.
Thanks, Chris, and good afternoon, everyone. We're very pleased to be here today to provide an update on our third quarter developments and what continues to be a highly productive year for CytomX as we advance our lead program, Varseta-M, towards its first potential registrational study in the first half of 2027. Varseta-M is an EpCAM-targeting Topo1 antibody-drug conjugate with strong potential in colorectal cancer and potentially other solid tumors. Importantly, to our knowledge, Varseta-M is first in class as the only EpCAM-directed ADC in clinical development. Varseta-M has been intentionally designed and uniquely enabled by our PROBODY platform, creating a significant opportunity for differentiation and long-term value creation. Strategically, we are initially developing Varseta-M in metastatic colorectal cancer as the lead indication.
Our sense of urgency for Varseta-M is driven by the significant unmet need in colorectal cancer, which is the second leading cause of cancer death in the U.S. and worldwide. Varseta-M is on the leading edge of ADC innovation in CRC and has the potential to be one of the first monotherapy ADCs to market for the treatment of this very challenging cancer type. In terms of commercial potential, there are an estimated 35,000 addressable patients in the U.S. with third-line or later CRC. Given the anti-cancer activity we have reported previously across an unselected late-stage patient population and the limited clinical benefit of existing therapies for these patients, we see considerable opportunity for Varseta-M. Based on Varseta-M's unique profile, we are actively advancing our development program across three strategic areas of priority.
First, we aim to move Varseta-M monotherapy into a registrational study in the first half of next year, enabling a potential first approval and meaningful market opportunity in metastatic CRC. Second, we continue our development of Varseta-M in combinations, including with bevacizumab and with earlier line chemotherapy regimens, with the goal of replacing current standard of care. Third, we have started to evaluate Varseta-M's pan-tumor potential across multiple EpCAM-expressing cancers, initially in additional gastrointestinal indications. The monotherapy Varseta-M phase I study has enrolled more than 100 patients across dose escalation, expansion, and optimization cohorts. As previously reported, patients enrolled in the phase I study have been heavily pre-treated, with most patients having received three or more prior treatments in the metastatic setting. In March, we reported encouraging progression-free survival at doses of 8.6 and 10 milligrams per kilogram that exceeded current standard of care.
We also shared our increasing understanding of the safety profile of Varseta-M, particularly how to lower and manage rates of high-grade diarrhea. This initial experience with Varseta-M in very late-line patients will provide us with a highly relevant dataset to enable monotherapy dose selection and inform the potential first registrational study design. Most recently, we have been highly focused on dose optimization, evaluating two doses, 8.6 and 10 milligrams per kilogram, given every three weeks, with adjusted ideal body weight dosing and upfront prophylaxis to manage gastrointestinal adverse events. We anticipate providing an integrated update in January across the phase I study, including our potential registrational strategy and the data that underpin our plans. It's important to note here that we expect this next update to provide the first look at overall survival for Varseta-M, which we anticipate will be the primary endpoint in our initial registrational study.
We look forward to providing this next update in the near term. Now moving on to the Varseta-M combination development program. Our ongoing phase I study evaluating Varseta-M in combination with bevacizumab continues to enroll late-line CRC patients to assess dose and safety. We view this combination as a foundational first step in evaluating Varseta-M's potential in earlier line CRC. Subject to data from the ongoing phase I study, we anticipate moving to earlier line CRC patients in the future evaluation of this combination, and we anticipate reporting initial clinical data from the bevacizumab combination in the first half of 2027. To also enable the use of Varseta-M in earlier lines of CRC therapy, we remain on track to initiate a study evaluating Varseta-M in combination with bevacizumab, five-fluorouracil, and leucovorin by the end of the year.
This study will be a new phase I/II trial that would enroll second-line CRC patients once phase I dose finding is successfully completed. We believe these Varseta-M combination studies have the potential to inform future development options and look forward to providing initial updates starting next year. Moving to the development of Varseta-M outside of CRC. Our strategy is to develop and ultimately commercialize Varseta-M across multiple EpCAM-expressing solid tumors, and we have recently initiated phase I cohorts in gastrointestinal indications with substantial unmet clinical need, and that we view as highly complementary to CRC from a commercial perspective. We have initiated cohorts in unselected gastric and gastroesophageal junction cancer, as well as EpCAM-selected pancreatic ductal adenocarcinoma and EpCAM-selected biliary tract cancer.
Each of these EpCAM-expressing tumor types currently have limited treatment options in later line settings and may present expedited development pathways for Varseta-M upon clinical proof of concept. Our initial plan is to enroll approximately 20 patients per tumor type to evaluate Varseta-M's anti-tumor activity and safety before assessing later phase development options. Having focused Varseta-M exclusively in CRC for the first two years of development, we are very excited to now be evaluating Varseta-M's broader clinical potential. Turning to CX-801, our masked interferon alpha-2b program being evaluated in checkpoint refractory melanoma. We see CX-801 as an exciting and broad opportunity to reprogram the immune responsiveness of solid tumors, and we continue to enroll the ongoing phase I study evaluating CX-801 as a monotherapy and in combination with KEYTRUDA.
Enrollment in the monotherapy cohort of our phase I study continues, having exceeded dose levels of the approved dose of unmasked interferon alpha-2b. Initial biomarker data for CX-801 monotherapy presented previously have reinforced our mechanism of action hypothesis for CX-801 in combination with KEYTRUDA. We continue to enroll in the combination cohort, and we look forward to sharing initial clinical data from the phase I study in melanoma in the first half of 2027. With those updates, let me now transition the call back to Chris.
Thank you, Sean. As Sean highlighted, we are making important progress across the Varseta-M program, including potentially moving towards later stage development. As we progress the broadening Varseta-M development program, we have continued to maintain an efficient and flexible cost structure, enabling us to pursue the opportunities Sean described earlier. To that end, with our current balance sheet, we project cash runway into the second half of 2028. Importantly, our runway funds our key value creation priorities that Sean outlined, including advancing Varseta-M into its first potential registrational study, pursuing combination development to move Varseta-M into earlier lines of CRC, and then expanding into multiple other EpCAM-expressing gastrointestinal tumors. With that, I am going to walk through our third quarter financial results. As of September 30, 2026, we ended the quarter with $348 million in cash equivalents, and investments, versus $330 million in cash as of June 30, 2026.
The cash balance as of September 30, 2026, includes $37 million received from Regeneron following its selection of two additional targets under the recently expanded collaboration. Looking at revenue and operating expenses for the quarter, total revenue was $1.7 million compared to $6 million in the third quarter of 2025. The decrease in revenue was primarily attributed to the conclusion of the Astellas collaboration in the second quarter of 2026. Operating expenses for the third quarter were $25.2 million compared to $21.7 million in the third quarter of 2025. Research and development expenses were $16.5 million during the third quarter, representing an increase of $1.2 million versus the third quarter of 2025, primarily due to increased personnel-related costs and partially offset by lower Varseta-M spending due to the timing of manufacturing activities.
General and administrative expenses increased by $2.3 million during the three months ending September 30, 2026, to $8.7 million, compared to $6.4 million for the corresponding period in 2025. Increased G&A expenses were primarily driven by personnel-related expenses and higher consulting spend. As we move towards 2027, we will continue to be disciplined in capital allocation in order to progress the most compelling Varseta-M development priorities and realize the broader value creation potential for CytomX stakeholders. With that, operator, let's go ahead and open up the call for Q&A.
Thank you. At this time, we will conduct a question-and-answer session. To ask a question, you will need to press star 11 on your telephone for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Paul Jeng of Guggenheim. Your line is now open.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
